S. Bailey

发表

Physiochemical drug properties associated with in vivo toxicological outcomes.

J. Hughes, Enoch S. Huang, David A. Price, 2008, Bioorganic & medicinal chemistry letters.

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.

D. Knighton, K. Liu, M. Yin, 2010, ACS medicinal chemistry letters.

4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.

D. Knighton, M. Nambu, K. Liu, 2010, Bioorganic & medicinal chemistry letters.

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos

Wei Liu, Huichun Zhu, Dac Dinh, 2014, Journal of medicinal chemistry.

Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.

G. Paderes, N. Sach, K. Liu, 2011, ACS medicinal chemistry letters.

Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant

Huichun Zhu, Benjamin J. Burke, John Charles Kath, 2014 .

Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.

P. Fish, S. Bailey, James E. J. Mills, 2008, Bioorganic & medicinal chemistry letters.

Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors.

K. Liu, M. Yin, P. A. Wells, 2012, Bioorganic & medicinal chemistry letters.

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.

Paolo Vicini, Deepak Dalvie, Chengyi Zhang, 2017, Journal of medicinal chemistry.

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).

Ping Chen, Hong Shen, M. Pairish, 2020, Journal of medicinal chemistry.

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.

N. Sach, Hong Shen, M. McTigue, 2014, Journal of medicinal chemistry.

Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).

S. Kazmirski, M. Hickey, G. Alton, 2011, Journal of medicinal chemistry.

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Deepak Dalvie, Michael Zientek, Rose Ann Ferre, 2016, Journal of medicinal chemistry.

Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design

D. Knighton, M. Edwards, S. Bagrodia, 2010 .

Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.

Julian Blagg, P. Fish, R. Butt, 2007, Journal of medicinal chemistry.

Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.

N. Sach, M. McTigue, H. Zou, 2013 .

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

K. Gajiwala, N. Sach, Sherry L. Niessen, 2016, Journal of medicinal chemistry.